Vicore Pharma Holding Management
Management criteria checks 2/4
Vicore Pharma Holding's CEO is Ahmed Mousa, appointed in Jan 2023, has a tenure of 3.5 years. total yearly compensation is SEK11.78M, comprised of 48.3% salary and 51.7% bonuses, including company stock and options. directly owns 0.038% of the company’s shares, worth $122.39K. The average tenure of the management team and the board of directors is 1 years and 3.2 years respectively.
Key information
Ahmed Mousa
Chief executive officer
SEK 11.8m
Total compensation
| CEO salary percentage | 48.34% |
| CEO tenure | 3.5yrs |
| CEO ownership | 0.04% |
| Management average tenure | 1yr |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -SEK 475m |
| Dec 31 2025 | SEK 12m | SEK 6m | -SEK 477m |
| Sep 30 2025 | n/a | n/a | -SEK 424m |
| Jun 30 2025 | n/a | n/a | -SEK 371m |
| Mar 31 2025 | n/a | n/a | -SEK 312m |
| Dec 31 2024 | SEK 8m | SEK 5m | -SEK 169m |
| Sep 30 2024 | n/a | n/a | -SEK 196m |
| Jun 30 2024 | n/a | n/a | -SEK 200m |
| Mar 31 2024 | n/a | n/a | -SEK 213m |
| Dec 31 2023 | SEK 6m | SEK 1m | -SEK 311m |
Compensation vs Market: Ahmed's total compensation ($USD1.21M) is below average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Ahmed's compensation has increased whilst the company is unprofitable.
CEO
Ahmed Mousa (42 yo)
Mr. Ahmed S. Mousa, J.D., serves as Chief Executive Officer at Vicore Pharma Holding AB (publ) since 2023. He served as General Counsel at Pieris Pharmaceuticals, Inc., since October 2018 until September 1...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 3.5yrs | SEK 11.78m | 0.038% $ 122.2k | |
| Chief Financial Officer | 9.1yrs | no data | 0.0037% $ 12.0k | |
| Chief Operating Officer | 2.5yrs | no data | 0.0035% $ 11.3k | |
| Chief Technology Officer | less than a year | no data | 0.0058% $ 18.6k | |
| Chief Scientific Officer | no data | no data | no data | |
| Chief Administrative Officer | 17.5yrs | no data | 0% $ 0 | |
| VP of Investor Relations | 2.5yrs | no data | no data | |
| General Counsel | less than a year | no data | no data | |
| Head of Non-Clinical Development | less than a year | no data | 0% $ 0 | |
| Chief Business Officer | less than a year | no data | 0.0044% $ 14.2k | |
| Head of Quality Assurance | 1.5yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
Experienced Management: VCRE's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 8.5yrs | SEK 627.00k | 0.0046% $ 14.7k | |
| Independent Director | 2.2yrs | SEK 627.00k | 0.015% $ 48.7k | |
| Independent Director | 2.2yrs | SEK 548.00k | no data | |
| Independent Chairman | 7.9yrs | SEK 1.59m | 0.017% $ 55.4k | |
| Director | less than a year | no data | no data | |
| Independent Director | 3.2yrs | SEK 665.00k | 0.011% $ 35.1k | |
| Independent Director | 6.2yrs | SEK 778.00k | 0.0018% $ 5.7k |
Experienced Board: VCRE's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 22:20 |
| End of Day Share Price | 2026/07/23 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vicore Pharma Holding AB (publ) is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Steven Seedhouse | Cantor Fitzgerald & Co. |
| Gonzalo Artiach Castanon | Danske Bank |
| Patrik Ling | DNB Carnegie |